Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study

Guadaño, E Martí; Serra-Batllés, Joan; Meseguer, Juan; Castillo, José A. García del; Molina, Montserrat; Valero, Antonio; Picado, César

doi:10.1111/j.1398-9995.2004.00576.x

Cited by 53 publications

(47 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…58 Rupatadine 10mg once daily was compared to ebastine 10 mg once daily and placebo. 59 Significant differences were detected in DTSSm between RU treatment and placebo (33% lower for RU group; p=0.005) after two weeks of treatment. Total symptom scores were 22% lower for RU than for ebastine; however, this could not reach statistical significance.…”

Section: Seasonal Allergic Rhinitismentioning

confidence: 90%

Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis

Katiyar

Prakash

2008

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a disease with high prevalence. In AR, exposure to airborne allergens elicits an allergic response which involves epithelial accumulation of effector cells -e.g. mast cells and basophils -and subsequent inflammation. During the early response in AR, histamine has been found to be the most abundant mediator and it is associated with many symptoms of this disease mediated through the histamine H1 receptor. Therefore, anti-histamines have a role to play in the management of AR. However, the available antihistamines have certain well-known side effects like sedation and potential pro-arrythmic effects owing to their interactions with other drugs, as well as having poor or no effect on platelet activating factor (PAF) which also plays an important role in AR. This article is a qualitative systematic literature review on the pharmacological profile of rupatadine in order to evaluate its safety and efficacy in AR as compared to other anti-histamines. Rupatadine is a once-daily non-sedative, selective, long-acting H1 anti-histamine with antagonistic PAF effects through its interaction with specific receptors. Rupatadine significantly improves nasal symptoms in patients with AR. It has a good safety profile and is devoid of arrythmogenic effects. These properties make rupatadine a suitable first line anti-histamine for the treatment of AR.

show abstract

Section: Seasonal Allergic Rhinitismentioning

confidence: 90%

Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis

Katiyar

Prakash

2008

Primary Care Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…This pathway could be a pharmacological target through the use of PAF-R antagonists, including rupatadine, a novel antihistamine/PAF-R antagonist which has been shown to be effective for allergic rhinitis (36).…”

Section: Discussionmentioning

confidence: 99%

Staphylococcal lipoteichoic acid inhibits delayed-type hypersensitivity reactions via the platelet-activating factor receptor

Zhang

Mousdicas

et al. 2005

Journal of Clinical Investigation

View full text Add to dashboard Cite

Finally, we measured levels of LTA that were adequate to stimulate PAF-R in vitro on the skin of subjects with infected atopic dermatitis. Based on these studies, we propose that LTA exerts immunomodulatory effects via the PAF-R through production of the Th2 cytokine IL-10. These findings show a novel mechanism by which staphylococcal infections can inhibit Th1 reactions and thus worsen Th2 skin diseases, such as atopic dermatitis.

show abstract

“…Their clinical effect in trials of perennial rhinitis lasting 4 weeks and over is usually small. Oral H 1 -antihistamines improve the patientÕs QOL (1066,1077,1479). One double-blind, placebo-controlled longterm trial found that levocetirizine was cost-effective in the treatment of PER (1066, 1115).…”

Section: 22mentioning

confidence: 99%